The long term objective of this research is to improve chemotherapy of cancer by using novel antifolates or novel reduced-folate analogs for biochemical modulation to yield an increased therapeutic index. The approach to be used may also define the role of antifolyl- and folylpolyglutamate metabolites in cytotoxicity and selectivity. The antifolate methotrexate (MTX) is clinically effective in combination chemotherapy regimens, but its efficacy is often limited by resistance which cannot be overcome at higher doses because toxicity is reached, i.e., it is not selective enough. Polyglutamates of MTX are implicated in its cytotoxicity as a single agent, but their contribution to cytotoxicity and (particularly) selectivity in combinations using this agent are unknown. Exogenous reduced folates (as leucovorin (LV); 5-formyltetra- hydrofolate) are used to """"""""rescue"""""""" from the cytotoxic effects of MTX and to augment the cytotoxicity of other drugs (e.g., 5-fluorouracil [FU]). The role of folylpolyglutamate synthesis in achieving these effects as well as in host toxicity and selectivity are unknown. This proposal will determine whether substitution of nonpolyglutamylatable analogs of MTX and LV in combination chemotherapy yields any therapeutic advantage. The analogs of MTX and LV will contain 4-fluoroglutamate instead of glutamate, a change sufficient to block polyglutamylation of the analog. The proposed studies of drug combinations will compare the biochemical, cytotoxic, and therapeutic effects of LV or MTX in a regimen with the same regimen containing these nonpolyglutamylatable """"""""mimics"""""""". Cytotoxicity will be assessed by out-growth and/or clonogenic assays using the human leukemia cell line CCRF-CEM and an appropriate murine model (for extension to in vivo therapeutic studies); time and dose dependence will be investigated in detail. Where feasible the biochemical determinants of cytotoxicity will be explored. The regimens to be investigated are: sequential MTX/5FU, simultaneous LV/5-FU, and LV rescue of MTX cytotoxicity. MTX and LV and their respective fluorinated """"""""mimics"""""""" will be compared to determine if they are biochemically equivalent, except for polyglutamylation. If the analogs are true """"""""mimics, the results from the cytotoxicity and efficacy studies would yield basic knowledge about the role of polyglutamates in these combinations. It is hoped that the knowledge gained in these studies will provide a basis for more sophisticated therapy protocols with improved efficacy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA013038-22S2
Application #
5206530
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
22
Fiscal Year
1996
Total Cost
Indirect Cost
Ojima, Iwao; Borella, Christopher P; Wu, Xinyuan et al. (2005) Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents. J Med Chem 48:2218-28
Berleth, E S; Nadadur, S; Henn, A D et al. (1999) Identification, characterization, and cloning of TIP-B1, a novel protein inhibitor of tumor necrosis factor-induced lysis. Cancer Res 59:5497-506
Huang, B G; Bobek, M (1998) Synthesis and in vitro antitumor activity of some amino-deoxy 7-hexofuranosylpyrrolo[2,3-d]pyrimidines. Carbohydr Res 308:319-28
Ojima, I; Bounaud, P Y; Takeuchi, C et al. (1998) New taxanes as highly efficient reversal agents for multidrug resistance in cancer cells. Bioorg Med Chem Lett 8:189-94
Ehrke, M J; Verstovsek, S; Pocchiari, S K et al. (1998) Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation. Int J Cancer 76:579-86
Yin, M B; Guo, B; Voigt, W et al. (1998) Novel cellular determinants for reversal of multidrug resistance in cells expressing P170-glycoprotein. Biochim Biophys Acta 1401:265-76
Ehrke, M J; Verstovsek, S; Ujhazy, P et al. (1998) Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother 45:287-98
Fogel-Petrovic, M; Kramer, D L; Vujcic, S et al. (1997) Structural basis for differential induction of spermidine/spermine N1-acetyltransferase activity by novel spermine analogs. Mol Pharmacol 52:69-74
Sharma, A; Glaves, D; Porter, C W et al. (1997) Antitumor efficacy of N1,N11-diethylnorspermine on a human bladder tumor xenograft in nude athymic mice. Clin Cancer Res 3:1239-44
Kramer, D L; Fogel-Petrovic, M; Diegelman, P et al. (1997) Effects of novel spermine analogues on cell cycle progression and apoptosis in MALME-3M human melanoma cells. Cancer Res 57:5521-7

Showing the most recent 10 out of 135 publications